Geneva, Switzerland and Boston, MA – March 29, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Month: March 2019
Nolasiban Set to Revolutionise Fertility: Interview in ‘The Times’ with ObsEva CEO, Ernest Loumaye
Co‐administration of the prostaglandin F2α receptor antagonist pre‐term labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone
Oliver Pohl, Line Marchand, Jean‐Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch
Safety and Pharmacokinetics of the Oral Prostaglandin F2alpha Receptor Antagonist, OBE022, in Patients With Threatened Spontaneous Preterm Labor
Andrew Humberstone, Jose Luis Bartha, Seppo Heinonen, Juha Räsänen, Aydin Tekay, Michel Brethous, Jean-Pierre Gotteland, Oliver Pohl, Ernest Loumaye
SRI Conference, 12-16 March 2019, Paris, France
Abstract S-001: page 299A
Abstracts. Reprod. Sci. 26, A62–A390 (2019). https://doi.org/10.1177/1933719119834079
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
Geneva, Switzerland and Boston – March 13, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
ObsEva Short Report 2018
Annual Report 2018
ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update
Major 2018 Accomplishments Driven by Positive Clinical Trial Results –Significant increase in rates of pregnancy and live birth (up to…
Q4 2018 ObsEva SA Earnings Conference Call
Click here for webcast Title Q4 2018 ObsEva SA Earnings Conference Call Date / Time 05 Mar 2019 8:00 a.m. ET /…